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Abstract 
Introduction: Chlamydia antibody testing (CAT) in serum has been introduced as a screening method in the infertility workup. We evaluated 
the test characteristics of two ELISA tests compared to micro-immunofluorescence tests (MIFs).  MIFs are considered the gold standard in 
the C. trachomatis IgG antibodies detection. We also compared the accuracy of all CAT tests in predicting tubal subfertility, using 
laparoscopy as a reference.  
Methodology: Four commercial serological methods were used to analyse 101 serum samples for the presence of C. trachomatis IgG 
antibodies from patients at the Infertility Clinic of Ghent University Hospital. The diagnostic utility for prediction of tubal infertility of 
serological methods was evaluated based on patients’ medical records. 
Results: A comparison of the serological assays showed  little difference  in the major performance characteristics: the sensitivities of all 
MIFs and ELISAs were 100% for all assays (except the ELISA Vircell, with a sensitivity of 90%), and the specificities ranged from 92% for 
MIF Ani Labsystems to 98% for the MIF Focus and ELISA Vircell. As compared to laparoscopy data, CAT positivity in subfertile women 
with tubal damage (n=40) did not significantly differ from that of subfertile women without tubal damage (n=61): Positive predictive values 
(PPV) of CAT ranged from 53% to 60% and negative predictive values (NPV) ranged from 62% to 64%.   
Conclusion: evaluated ELISAs are comparable to MIFs in the detection of C. trachomatis IgG antibodies and should be preferred for large 
serological studies, especially in resource poor settings. 
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Introduction 
Chlamydia trachomatis is the commonest 
sexually transmitted bacterial infection in the world 
[1,2]. In women, up to 80% of C. trachomatis 
infection is asymptomatic; thus few infected women 
seek medical care, resulting in continued 
transmission to sexual partners [1]. These untreated 
women are at risk of developing chronic sequelae 
such as periadnexal adhesions and tubal occlusion. 
Tubal pathology is one of the causes of subfertility 
being responsible for 10% to 30% of the cases in 
developed countries and up to 85% in developing 
countries [3-5]. The reference method of assessment 
for tubal damage is laparoscopy and, when 
laparoscopy is not available such as in low-resource 
diagnostic settings, hysterosalpingography can be 
used [6]. However, both methods are costly and 
invasive, and therefore unsuitable for screening on a 
large scale. Since tubal pathology and infertility have 
been associated with asymptomatic Chlamydia 
trachomatis infections in the past, chlamydia 
antibody testing (CAT) in serum has been introduced 
as a screening method for tubal factor subfertility [7-
10]. Hence the development of a simple and reliable 
assay for the detection of C. trachomatis antibodies is 
essential. 
The micro-immunofluorescence test (MIF) is 
generally regarded as a gold standard in the 
serological diagnosis of C. trachomatis infection 
[11,12]. However, MIF is not ideal for routine 
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serodiagnostics because it is labour intensive, highly 
observer dependent, and interlaboratory variation is 
significant[13]. Enzyme immunoassays (EIA) based 
on synthetic peptides characterized by high 
throughput, objective endpoints, and technical 
accessibility are commercially available [14],  but are 
generally considered to be inferior to MIF in 
predicting tubal factor subfertility [15].   
The aim of this study was to evaluate the 
possibility of the use of ELISA tests for fast 
throughput of large numbers of sera, to be used 
particularly in a study foreseen to investigate the 
association of tubal pathology and past chlamydia 
infection in Rwanda, a developing country. Their 
performances were evaluated against those of two 
microimmunofluorescence assays for the detection of 
Chlamydia trachomatis IgG antibodies in sera of 
subfertile women. Secondly, we compared all CAT in 
their accuracy to predict tubal subfertility using 
laparoscopy. 
 
Methodology 
Sera of patients, who underwent a laparoscopy as 
a part of the infertility workup at the Infertility Clinic 
at Ghent University Hospital between September 
2005 and May 2007, were included in the study. The 
sera were stored at -20°C prior to analyses. A total of 
101 sera were analysed, comprising 40 (39.6%) sera 
from patients with tubal damage and 60 (60.4%) sera 
from patients without tubal damage as assessed by 
laparoscopy. Tubal damage at laparoscopy was 
defined as extensive periadnexal adhesions and/or 
distal or proximal occlusion of one or both fallopian 
tubes. After thawing the cryopreserved sera, four 
different CAT tests were performed and the results 
were correlated to the laparoscopy data. The study 
was approved by the Ghent University Hospital 
Ethics Committee under Belgian Registration 
Number B67020072676. 
 
Serological methods 
Chlamydia pneumoniae Ig G/Ig M Micro-IF test: 
The Chlamydia pneumoniae Ig G/Ig M Micro-IF test 
(Ani Labsystems Ltd., Vantaa, Finland) is a species-
specific test based on indirect detection of C. 
pneumoniae, C. trachomatis and C. psittaci 
antibodies. In short, patient’s serum was diluted 1:8 
in phosphate-buffered saline (PBS) and incubated on 
the microscope slides dotted with three Chlamydia 
antigens for 30 minutes at 37°C in a moist chamber. 
The slides were washed twice with PBS and twice 
with distilled water and incubated with goat anti-
human IgG-fluorescein isothiocyanate conjugate for 
30 minutes at 37°C. The slides were washed twice 
again with PBS and twice with distilled water. 
Mounting fluid was added on the slides, and a cover 
slip was placed. The slides were read using a Leitz 
Laborlux 12 fluorescent microscope (WILD Leitz, 
Heerbrugg, Germany) with 25x objective by two 
independent readers. In case of disagreement, the 
judgement of a third reader was decisive. For a 
quantitative determination of endpoint titres, serial 
dilutions in PBS were performed. For C. trachomatis, 
a titre of 1:32 was considered the cut-off for 
positivity according to the manufacturer's 
instructions. 
Chlamydia Micro-IF IgG test (Focus Diagnostic, 
Cypress, USA): This micro-immunofluorescence 
antibody assay is a two-stage “sandwich” procedure. 
In the first stage, the patient sera were diluted in PBS. 
The diluted sera were added to appropriate slide 
wells in contact with the substrate, and incubated for 
30 minutes. Following incubation, the slide was 
washed twice with PBS and twice with distilled 
water. In the second stage, each well was overlaid 
with fluorescein-labelled antibody to IgG and 
incubated for 30 minutes. After the slide was washed, 
dried, and mounted, it was examined using a Leitz 
Laborlux 12 fluorescent microscope (WILD Leitz, 
Heerbrugg, Germany) with 25x objective by two 
independent readers. In case of disagreement, the 
judgement of a third reader was decisive. For a 
quantitative determination, serial dilutions in PBS 
were performed. According to the manufacturer's 
instructions, a serum was considered to be MIF IgG 
positive if it was reactive at a dilution of 1:16. 
Chlamydia trachomatis IgG EIA (Ani 
Labsystems Ltd., Vantaa, Finland): This test was 
developed for the detection of species-specific IgG 
antibodies to surface-expressed peptides of C. 
trachomatis. Sera were tested manually according to 
the manufacturer’s instruction. Briefly, sera diluted 
1:100 in PBS were incubated with the C. trachomatis 
antigens coated onto a 96-well plate. After washing, 
horseradish peroxidase-conjugated anti-
immunoglobulin (IgG) was added to the wells and 
incubated for 30 minutes at 37°C. After further 
washing, the chromogen containing 
tetramethylbenzindine was added. The reaction was 
stopped with sulphuric acid after 15 minutes and 
optical density was read immediately at 450 nm using 
a BEP III Behring ELISA Processor (Siemens AG, 
Erlangen, Germany) spectrophotometer. The signal to 
cut-off indices was categorized per the 
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manufacturer’s instructions as negative, equivocal 
and positive. 
Chlamydia trachomatis ELISA IgG/IgM (Vircell, 
Santa Fe, Spain): Synthetic peptides derived from 
complexes of outer membrane proteins (COMP) 
of C. trachomatis free from lipopolysaccharide (LPS) 
were used in this indirect enzyme immunoassay.  
Sera were tested manually according to the 
manufacturer’s instructions. In short, sera were 
diluted 0.5:100 in PBS and tested in microplates 
coated with C. trachomatis antigens. The plates were 
incubated for 45 minutes at 37°C in a chamber. The 
plates were washed five times with PBS. To each 
well, conjugate (goat anti-human IgG, horseradish 
peroxidase-conjugated) was added and the plates 
were incubated for 30 minutes at 37°C. The plates 
were washed again five times with PBS. To each 
well, tetramethylbenzidine substrate was added and 
the plates were incubated for 20 minutes at room 
temperature. Finally, sulphuric acid was added to 
stop the colouring reaction. The optical density of the 
plates was measured at 450 nm using a BEP III 
Behring ELISA Processor (Siemens AG, Erlangen, 
Germany) spectrophotometer. Threshold indexes 
were calculated according to the manufacturer's 
instructions as negative, equivocal and positive. 
 
Statistical analysis 
For statistical analysis SPSS 11.5 for windows 
programme (SPSS Inc., Chicago, USA) was utilized. 
For the comparison of the ELISA tests to the MIF 
assays and the test ability to detect tubal pathology, 
two-by-two tables were used to calculate sensitivity, 
specificity, positive predictive value (PPV), negative 
predictive value (NPV), and odds ratio (OR). The 
chi-square test was used to test significance of the 
difference in frequency distribution. A p-value of < 
0.05 was considered as significant. 
 
Results 
Four different commercial serological assays 
were applied to 101 sera taken from subfertile 
women. The C. trachomatis seropositivity ranged 
from 9.9% with Vircell ELISA to 16.9% with Ani 
Labsystems MIF (Table 1). The concordances of the 
IgG results for all of the different assays are shown in 
Table 2. Diagnostically significant reactions were 
found in 19 patients. In nine patients all four CAT 
tests were positive, whereas only one patient had 
three positive tests, three patients had two positive 
tests and six patients had one positive test.  
 
Further comparison of the assays was done on the 
basis of the current gold standard, MIF. Since the 
results of the two different MIFs were not 
homogeneous, we defined a positive sample as one 
that was positive by the two MIFs [16]. Based on this 
internal standard, we found that 10 (10%) samples 
were positive and 91 (90%) samples were negative. 
In addition, by using our internal gold standard, we 
determined the specificities, sensitivities, PPVs and 
NPVs of the different tests (Table 3). The 
sensitivities of all MIFs and ELISAs for the detection 
of C. trachomatis antibodies were 100 % for all 
assays except the Vircell ELISA, for which the 
sensitivity was 90%. The specificities were 98% for 
the MIF from Focus and ELISA from Vircell, 96 % 
for the Ani Labsystems ELISA, and 92% for Ani 
Labsystems MIF. The PPVs were 90% for MIF from 
Focus and ELISA from Vircell, 76 % for the Ani 
Labsystems ELISA, and 58 % for the Ani 
Labsystems MIF. All assays had relatively high NPV 
between 98% and 100%. 
The results of four different CAT tests and 
laparoscopy in 101 subfertile women are presented in 
Table 4. As compared to laparoscopy data, CAT 
positivity in subfertile women with tubal damage (n = 
40) did not significantly differ from that of subfertile 
women without tubal damage (n = 61). None of the 
evaluated serological assays had acceptable PPV 
(from 53% for ELISA Ani Labsystems to 60% for 
ELISA Vircell) and NPV (from 62% for MIF Focus, 
ELISA Ani Labsystems and ELISA Vircell to 64% 
for MIF Ani Labsystems).  
 
Discussion 
This study was designed to compare the 
performance of four different commercially available 
tests for the detection of C. trachomatis specific IgG 
antibodies in sera of 101 subfertile women. The 
second objective of the study was to evaluate 
diagnostic utility of serology in the prediction of 
tubal infertility as compared to laparoscopic findings. 
Two different versions of MIF (including the 
recently developed MIF Focus), the current gold 
standard for the serodiagnosis of Chlamydia 
infection, were included in the study, as were two 
ELISAs, which differed in the particular antigen 
preparations used. In general, these peptide-based 
assays performed as well as the MIF assay. 
In the present study, seroprevalence rates of the 
two ELISA assays were similar to those of the Vircell 
MIF assay (9.9-12.9%), whereas the Ani Labsystems 
MIF showed higher seroprevalence  
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(16.8%), possibly due to a higher rate of false-
positive results. 
Based on our internal gold standard, the test 
characteristics of both MIFs, including the recently 
developed MIF Focus and two ELISAs for the 
detection of serological evidence of C. trachomatis 
infection, were similar. All tests had reasonably high 
sensitivity, specificity, and NPV and would therefore 
match the criteria of a screening test (Table 3). Thus 
far, few studies have compared these new serological 
assays with the MIF assay. The findings of our study 
are consistent with previous studies that revealed 
good sensitivities and specificities of ELISA assays 
based on peptides from the major outer membrane 
protein (MOMP) [15,17]. Paukku et al. [18]  
 
 
 
 
 
 
 
compared the MIF assay to the ELISA Ani 
Labsystems for 78 patients with tubal factor 
infertility and showed a good correlation between the 
results of these assays. Morré et al. [19],  in a study 
involving 43 women with PCR positive cervical 
swabs for C. trachomatis, showed that the results of 
the ELISA tests correlated well with the antibody 
results for C. trachomatis obtained by the MIF tests.  
The association of serum IgG antibodies to C. 
trachomatis and tubal pathology is commonly known 
[20,21]. In the present work, we observed that C. 
trachomatis antibody positivity in subfertile women 
with tubal damage did not differ significantly from 
that of subfertile women without tubal damage (Table 
1).  Although not reaching significant levels, a trend  
 
Test 
Number of 
women with 
Number of 
women with Sensitivity  Specificity  PPV  NPV  OR(95%CI) p-value 
  
positive CAT 
test  
positive test 
and TD  (%) (%) (%) (%)     
MIF Ani  
Labsystems 17 10 25 88 58 64 2.5 (0.9-7.4) NS 
MIF Focus 11 6 15 91 54 62 1.9 (0.5-6.9) NS 
ELISA Ani 
Labsystems 13 7 17 90 53 62 1.9 (0.6-6.2) NS 
ELISA 
Vircell 10 6 15 93 60 62 2.5 (0.6-9.5) NS 
         
Number of  
Test with positive result 
Number of  Accumulated  
 positive positive 
Positive tests women cases 
4 MIF Anilabsystem, MIFFocus, ELISA Anilabsystem, ELISA Vircell 9 9 
3 MIF Anilabsystem, MIFFocus, ELISA Anilabsystem 1 1 
2 MIFFocus, ELISA Anilabsystem 2   
  MIF Anilabsystem, ELISA Anilabsystem 1   
  MIF Anilabsystem, ELISA Vircell 1   
  Total 4 4 
1 MIF Anilabsystem 4   
  ELISA Anilabsystem 1   
        
  Total 5 5 
0   82 19 
Table 1. C. trachomatis antibody testing by four different serological assays and laparoscopical data on tubal damage (TD) in 
101 subfertile women 
 
NS: Not significant 
 
Table 2. Diagnostically significant reactions of different serological tests 
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toward a higher seroprevalence in the group of 
women with tubal damage was observed for all CAT 
tests. Our findings are consistent with those of an 
earlier published critical reappraisal [21] of the 
literature on screening for tubal factor subfertility by 
CAT tests. CAT screening as a strategy reveals 
heterogeneous results and the meta-analysis indicates 
that the predictive value of CAT for tubal pathology 
is limited: the sensitivity of CAT varies between 30% 
and 88%, and the specificity varies between 45% and 
100%. In a recent study, there was also no significant 
difference found in C. trachomatis antibody 
positivity when 104 infertile women were compared 
with 80 fertile women [22]. In contrast, there are 
earlier published reports on the high predictive value  
 
 
 
 
 
 
 
 
 
 
of C. trachomatis antibody positivity on tubal 
damage [23,24]. Another study has shown that 
combined use of the CAT test and medical history 
taking has superior diagnostic accuracy over one of 
these approaches alone [25].  
The absence of a significant association of C. 
trachomatis-positive serology and tubal damage 
observed in our study and some of the others 
mentioned above [21,22]  is likely due to a relatively 
small sample size. Secondly, our findings are based 
on the use of retrospective laparoscopic data and are 
therefore lacking systematic information regarding 
the type of tubal abnormalities with the more 
stringent selection of the Chlamydia-associated 
pathology.  
Test Frequency of each outcome* Sensitivity Specificity PPV NPV 
 
True 
positive 
False 
positive 
True 
negative 
False 
negative 
(%) (%) (%) (%) 
MIF Ani 
Labsystems 
10 7 84 0 100 92 58 100 
MIF Focus 10 1 90 0 100 98 90 100 
ELISA Ani 
Labsystems 
10 3 88 0 100 96 76 100 
ELISA 
Vircell 
9 1 90 1 90 98 90 98 
Assays 
CAT 
Result 
Tubal 
damage 
n= 40 
Normal 
tube 
n= 61 
Sensitivity 
(%) 
Specifity 
(%) 
PPV NPV 
OR 
(95% CI) 
MIF Ani 
Labsystems 
Positive 10 7 25 88 58 64 
2.5 
(0.9-7.4) 
Negative 30 54 
     
MIF Focus 
Positive 6 5 15 91 54 62 
1.9 
(0.5-6.9) 
Negative 34 56 
     
ELISA Ani 
Labsystems 
Positive 7 6 17 90 53 62 
1.9 
(0.6-6.2) 
Negative 33 55 
     
ELISA Vircell 
Positive 6 4 15 93 60 62 
2.5 
(0.6-9.5) 
Negative 34 57 
     
Table 3. Sensitivities, specificities, PPVs, and NPVs of different assays in relation to the study’s internal gold standard 
(i.e., positive by both MIFs) 
 
*n = 101 
 
Table 4. C. trachomatis antibody testing by four different serological assays and laparoscopical data on tubal damage 
(TD) in 101 subfertile women 
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 Of particular note, Chlamydia antibodies are 
associated with Chlamydia-induced tubal pathology 
only, and, as a consequence, the predictive value of 
CAT will be poor for disease not associated with 
Chlamydia infection. It has been shown that CAT is 
more accurate in predicting distal tubal pathology, 
instead of unspecified tuboperitoneal abnormalities or 
proximal tubal occlusion [11].  Moreover, in studying 
the implications of different cutoff titres for a 
positive test, it has been noted that increasing the 
cutoff titre will improve the specificity, at the 
expense of sensitivity [7,12,15]. In patients with 
laparoscopically detected tubal pathology but 
negative antibody titres, diminished antibody titres 
related to time has been considered by some authors 
but not by others [26,27]. Finally, immunity status in 
C. trachomatis infection has not yet been fully 
understood but there is growing evidence that 
persistent C. trachomatis infections present an 
important risk group for tubal pathology [8].  
In conclusion, our data show that the two 
ELISAs performed equally as well as or slightly 
better than MIF assays for the detection of antibodies 
to C. trachomatis. Since these ELISA tests are easier 
to perform, less expensive, and able to be read more 
objectively than the MIF assay, they might be good 
alternatives to the MIF assay for the detection of C. 
trachomatis antibodies, especially when a large 
number of samples are to be processed. However, 
with all CAT tests evaluated, a trend toward a similar 
higher seroprevalence in the group of women with 
tubal damage was observed that did not reach 
significance, likely due to the relatively small sample 
size in this study. 
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